SCHEMBL5486173

SCHEMBL5486173

COC(=O)Cc1cc(OC)c(OC)cc1C(=O)c1ccc(I)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
KMT2A Q03164 2/20 0.46
CASP3 P42574 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
MTNR1A P48039 3/20 0.43
MTNR1B P49286 3/20 0.43
NPSR1 Q6W5P4 2/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.41
GAA P10253 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5484957 0.86 KMT2A (0.49) POLBKMT2ACASP3SENP6MTNR1A
SCHEMBL5486180 0.86 CASP3 (0.58) POLBKMT2ACASP3SENP6MTNR1A
SCHEMBL5484029 0.78 MAPT (0.50) POLBKMT2ANPSR1MAPTHTT
SCHEMBL11800712 0.76 KDM4E (0.54) POLBKMT2ANPSR1MAPTHTT
SCHEMBL197773 0.76 HTT (0.53) MTNR1AMTNR1BNPSR1HTTGAA
SCHEMBL5486177 0.76 MAPT (0.46) POLBKMT2ANPSR1MAPTHTT
SCHEMBL5484025 0.76 MAPT (0.47) POLBKMT2ANPSR1MAPTHTT
SCHEMBL7419510 0.75 HSD17B10 (0.49) POLBKMT2AMTNR1AMTNR1BCYP3A4
SCHEMBL29025520 0.75 MTNR1A (0.60) KMT2AMTNR1AMTNR1BCYP3A4CYP1A2
SCHEMBL6617275 0.74 TSHR (0.53) POLBNPSR1MAPTHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250410-B2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof VIA PHARMACEUTICALS, INC. (US) 2007-07-31 US disclosed
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof PDE7A, PDE3B, PDE3A POLB 717/4885KMT2A 3175/4885CASP3 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.